NVCR - NovoCure Limited

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
35.90
-0.60 (-1.64%)
As of 10:45AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close36.50
Open36.40
Bid35.90 x 900
Ask36.00 x 800
Day's Range35.60 - 36.40
52 Week Range16.10 - 38.65
Volume53,976
Avg. Volume725,782
Market Cap3.321B
Beta3.14
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • What Does NovoCure’s Valuation Trend Indicate?
    Market Realist2 hours ago

    What Does NovoCure’s Valuation Trend Indicate?

    NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.

  • NovoCure Stock: Key Factors Driving Investors’ Interest
    Market Realist2 hours ago

    NovoCure Stock: Key Factors Driving Investors’ Interest

    NovoCure (NVCR) is mainly engaged in developing and bringing tumor treating fields for solid tumors to the market. The company’s first tumor treating fields delivery system, Optune, is targeted to treat adult patients with glioblastoma. Tumor treating fields use electric fields tuned to certain frequencies to disrupt solid tumor cancer cell division.

  • NovoCure’s Top Line Registered Strong Growth
    Market Realist2 hours ago

    NovoCure’s Top Line Registered Strong Growth

    NovoCure (NVCR) generated revenues of $61.51 million in the second quarter—compared to $38.38 million in the second quarter of 2017. The growth was also driven by NovoCure’s initial launch efforts in Japan. NovoCure incurred a cost of revenues of $19.83 million in the second quarter—compared to $13.15 million in the second quarter of 2017.

  • Benzinga2 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Canopy Growth Corp (NYSE: CGC ) stock gained more ...

  • Forget Bitcoin: You're Better Off Buying These 3 Stocks
    Motley Fool11 days ago

    Forget Bitcoin: You're Better Off Buying These 3 Stocks

    Cryptocurrencies might grab all of the headlines, but these three businesses are better bets for the long term.

  • NovoCure’s Revenues Rose 60% in the Second Quarter
    Market Realist21 days ago

    NovoCure’s Revenues Rose 60% in the Second Quarter

    NovoCure (NVCR) released its second-quarter results on July 26. In the second quarter, NovoCure continued to see steady growth in patient prescriptions for new glioblastoma diagnosis. NovoCure reported a net loss of $15.51 million in the second quarter—compared to a net loss of $21.17 million in the second quarter of 2017.

  • Thomson Reuters StreetEvents22 days ago

    Edited Transcript of NVCR earnings conference call or presentation 26-Jul-18 12:00pm GMT

    Q2 2018 Novocure Ltd Earnings Call

  • Why Most Analysts Are Bullish on NovoCure
    Market Realist23 days ago

    Why Most Analysts Are Bullish on NovoCure

    NovoCure (NVCR) is expected to incur SG&A (selling, general, and administrative) expenses of $35.4 million in the second quarter, compared with $31.38 million in the second quarter of 2017, an increase of 12.8%. NovoCure’s R&D (research and development) expenses are expected to increase 47.06% from $9.37 million in the second quarter of 2017 to $13.78 million in the second quarter. NovoCure’s total operating expenses are expected to increase 18.1% from $40.75 million in the second quarter of 2017 to $48.13 million in the second quarter.

  • What to Expect from NovoCure’s Q2 2018 Earnings
    Market Realist23 days ago

    What to Expect from NovoCure’s Q2 2018 Earnings

    NovoCure (NVCR) is expected to report its second-quarter earnings on July 26. In this series, we’ll look at the company’s top-line, operational, and bottom-line performance expected by analysts for the second quarter. We’ll also look at analysts’ recommendations and the performance of NovoCure stock so far this year.

  • Market Realistlast month

    NASDAQ All-Stars

    Batting first and playing RF, we have GDS Holdings Ltd. (NASDAQ: GDS). GDS is one of the leading carrier-neutral data center solutions providers in China, and the growing demand for its services has led to impressive growth.

  • NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%
    Zackslast month

    NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%

    NovoCure (NVCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Here's Why Novocure Ltd. Rose 55% in the First Half of 2018
    Motley Foollast month

    Here's Why Novocure Ltd. Rose 55% in the First Half of 2018

    Fighting cancer with electric fields could be a huge business.

  • InvestorPlacelast month

    Trade of the Day: Novocure Ltd (NVCR)

    To receive further updates on this Novocure Ltd (NASDAQ:NVCR) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Power Options Weekly today.

  • TheStreet.com2 months ago

    NovoCure's Charts Look Bullish

    NovoCure Limited made a small base pattern in 2016 and started a strong rally in 2017 and moving up four-fold from its 2017 nadir. Let's review the charts and indicators of NVCR to see what the prospects look like for this company.

  • CNBC2 months ago

    Cramer's lightning round: The pecking order for my favorite cybersecurity stocks

    Jim Cramer zooms through his take on callers' favorite stocks and lists his top picks in the cybersecurity space.

  • The Probable Reason Behind NovoCure's Double-Digit Drop Today
    Motley Fool2 months ago

    The Probable Reason Behind NovoCure's Double-Digit Drop Today

    Shares retreat after the company releases details about an upcoming phase 3 trial. Should investors be worried, or is this just market noise?

  • Best Growth Stock in May
    Simply Wall St.3 months ago

    Best Growth Stock in May

    Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of NVCR earnings conference call or presentation 26-Apr-18 12:00pm GMT

    Q1 2018 Novocure Ltd Earnings Call

  • This Explains Why NovoCure Is Surging Today
    Motley Fool4 months ago

    This Explains Why NovoCure Is Surging Today

    Shares jumped even though the company reported worse-than-expected results. What's going on?

  • Associated Press4 months ago

    NovoCure: 1Q Earnings Snapshot

    On a per-share basis, the St. Helier, Jersey-based company said it had a loss of 23 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • NovoCure (NVCR) Shares March Higher, Can It Continue
    Zacks4 months ago

    NovoCure (NVCR) Shares March Higher, Can It Continue

    As of late, it has definitely been a great time to be an investor in NovoCure Limited (NVCR).

  • NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session
    Zacks4 months ago

    NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session

    NovoCure (NVCR) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.

  • 3 Top Healthcare Stocks to Buy in April
    Motley Fool4 months ago

    3 Top Healthcare Stocks to Buy in April

    April could be the perfect time to pick up shares in these top healthcare stocks.

  • Is NovoCure Limited’s (NASDAQ:NVCR) Balance Sheet A Threat To Its Future?
    Simply Wall St.4 months ago

    Is NovoCure Limited’s (NASDAQ:NVCR) Balance Sheet A Threat To Its Future?

    Investors are always looking for growth in small-cap stocks like NovoCure Limited (NASDAQ:NVCR), with a market cap of US$1.96B. However, an important fact which most ignore is: how financially healthyRead More...

  • Analysts Expect Breakeven For NovoCure Limited (NASDAQ:NVCR)
    Simply Wall St.5 months ago

    Analysts Expect Breakeven For NovoCure Limited (NASDAQ:NVCR)

    NovoCure Limited’s (NASDAQ:NVCR): NovoCure Limited engages in the development, manufacture, and commercialization of Tumor Treating Fields for the treatment of solid tumors. The US$2.00B market-cap company announced a latest lossRead More...